Study wrapper · #967
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.
Verma S, Böttcher M, Brown P, et al. Hypertension. 2026.
DOI: 10.1161/hypertensionaha.125.26055PubMed: 41328546
Editor's note
A secondary and post hoc analysis of the 68-week REDEFINE 1 phase 3 trial (3417 participants) examining blood pressure. CagriSema was associated with systolic reductions of about 11 mm Hg versus under 3 mm Hg for placebo, including among participants with resistant hypertension. Strong human evidence for a cardiometabolic secondary endpoint.
Plain-language abstract
In this phase 3 trial analysis, the cagrilintide-semaglutide combination was associated with larger blood pressure reductions than placebo in adults with overweight or obesity.
Related coverage
Mixed
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Lancet (London, England)n=——2026
Supported
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
The lancet. Diabetes & endocrinologyn=——2026
Supported
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Lancet (London, England)n=——2026